What We're Reading: Page 334
Industry reads hand-picked by our editors
Jul 15, 2016
-
Stat
For cancer patients on experimental immunotherapy drugs, it’s been an emotional week
-
Reuters
UK charity pockets $150 million from Merck cancer immunotherapy drug
-
Bloomberg
Martin Shkreli Back in the Spotlight as Musical Theater Villain
-
KQED Science
The Rise and Fall of Theranos: A Cartoon History
Jul 14, 2016
-
Wall Street Journal
Drugmakers' pricing power remains strong
-
Reuters
UCLA study finds why some cancers stop responding to immunotherapy
-
Stat
Senate sends first major opioids legislation to Obama's desk
-
New York Times
So many research scientists, so few openings as professors
-
CNBC
Valeant shares drop 3% after new short bet, ex-CEO stock sale
Jul 13, 2016
Jul 12, 2016
-
Endpoints
Sage claims another big win on a small study, this time for postpartum depression
-
EP Vantage
M&A – Value of deals looks healthy but number meagre
-
Stat
Senate delays Cures bill, as window for major legislation narrows
-
The Guardian
UK scientists dropped from EU projects because of post-Brexit funding fears
Jul 11, 2016
-
LA Times
Inside an L.A. OxyContin ring that pushed more than 1 million pills. What the drugmaker knew
-
New York Times
A medical mystery of the best kind: major diseases are in decline
-
Reuters
False hope? China's military hospitals offer illegal experimental cures
-
The Sydney Morning Herald
AIDS epidemic 'over' in Australia, say peak bodies
Jul 08, 2016
-
Reuters
Japan's Eisai weighs legal action in UK cancer drug row
-
MIT Technology Review
Biomedicine Blood Tests That Spot Cancer DNA Offer “Quantitative Peace of Mind” for Survivors
-
Regulatory Focus
FDA to Restrict Compounders from Making Copies of Commercially Available Drugs
-
AP
Painkiller panel drops experts linked to pharmaceutical industry
Previous
